AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAR 7 - (NewsRx.com & NewsRx.net) -- Women with advanced breast cancer are being sought to participate in an early phase study at UCLA's Jonsson Cancer Center that will test two biologically targeted compounds that seek to block the signals that cause cancers to grow.
The study of the drug Herceptin, approved in 1998 by the U.S. Food and Drug Administration for use against advanced breast cancer, combined with the experimental compound OSI-774 (Tarceva) does not use standard treatments such as chemotherapy and radiation.
A pill taken once daily, OSI-774 is designed to block a growth receptor that prompts the excess cell proliferation associated with cancer. Herceptin is administered in weekly infusions and works in a similar way, but targets a different growth receptor, said Dr. Carolyn Britten, a UCLA Jonsson Cancer Center researcher and coprincipal investigator in the study.
"This is a total biologic approach, and we hope it will be easier to tolerate than traditional therapies," said Britten, an ...
Source: HighBeam Research, Women with advanced disease sought for unique study at UCLA.(breast...